Suvankar Majumdar is an Oncology physician affiliated with Children's National. OpenAlex indexes 76 publications with 2,646 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
111 Michigan Ave NW
Washington, DC 200102916
Telephone
202-476-3800Registry record last updated 21 Jul 2022.
Clinical trials
- Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
Sponsor: Suvankar Majumdar
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SOBI, INCProgram year20256 payments$10,661openpaymentsdata.cms.gov ↗
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2024–2026 per NIH RePORTER. The latest:
- A randomized double-blind, placebo-controlled phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease
Children'S Research Institute
FY2026$859,703R33HL167806 - A randomized double-blind, placebo-controlled phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease
Children'S Research Institute
FY2025$859,704R33HL167806 - A randomized double-blind, placebo-controlled phase 2 clinical trial of intravenous citrulline for vaso-occlusive crisis in sickle cell disease
Children'S Research Institute
FY2024$776,011R61HL167806
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department
Contemporary Clinical Trials Communications
2023 - The evolution of the <scp>COVID</scp>‐19 pandemic in paediatric patients with sickle cell disease: From Alpha to Omicron
British Journal of Haematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Abdullah Feroze, MD
Children's National
David Jacobsohn, MD
Children's National
Stephan Ladisch, MD
Children's National
Naomi Luban, MD
Children's National
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”